Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849907 | 0.86 | TAS1R3 (0.40) | TAAR1IDO1RIPK1AOC3CYP3A4 | |
| SCHEMBL14402510 | 0.86 | TAS1R3 (0.40) | TAAR1IDO1RIPK1AOC3CYP3A4 | |
| SCHEMBL14402658 | 0.84 | RIPK1 (0.42) | TAAR1RIPK1LMNA | |
| SCHEMBL14402859 | 0.83 | TAAR1 (0.37) | TAAR1RIPK1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL20376166 | 0.83 | TAAR1 (0.43) | TAAR1IDO1RIPK1AOC3CYP3A4 | |
| SCHEMBL15067498 | 0.83 | TAAR1 (0.43) | TAAR1IDO1AOC3CYP3A4CYP2D6 | |
| SCHEMBL28558103 | 0.83 | TAAR1 (0.43) | TAAR1IDO1AOC3CYP3A4CYP2D6 | |
| SCHEMBL13003567 | 0.83 | TAAR1 (0.43) | TAAR1IDO1RIPK1AOC3CYP3A4 | |
| SCHEMBL27984832 | 0.81 | TAAR1 (0.38) | TAAR1IDO1AOC3CYP3A4CYP2D6 | |
| SCHEMBL15082795 | 0.81 | TAAR1 (0.45) | TAAR1IDO1AOC3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0321211-A1 | Antifungal carbinols | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-21 | — | — | EP | claimed |
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1334976-B1 | Novel phosphine compound, transition metal complex containing said compound as ligand and asymetric synthesis catalyst containing said complex | TAKASAGO PERFUMERY CO LTD (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-6717016-B2 | HAVING CHEMICAL SELECTIVITY, ENANTIOSELECTIVITY, CATALYTIC ACTIVITY; FOR USE AS A CATALYST FOR ASYMMETRIC SYNTHESES, ESPECIALLY ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-06 | — | — | US | disclosed |
| EP-1334976-A1 | Novel phosphine compound, transition metal complex containing said compound as ligand and asymetric synthesis catalyst containing said complex | Takasago International Corporation (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-0321211-A1 | Antifungal carbinols | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144139-A1 | Novel phosphine compound, transition metal complex containing the same phosphine compound as ligand and asymmetric synthesis catalyst containing the complex | PHOSPHO1, MEN1, PDCD1 | TAAR1 2152/4885IDO1 1876/4885RIPK1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.